Meeting
2021 ASCO Annual Meeting
NRG-RTOG 1106/ACRIN 6697: A phase IIR trial of standard versus adaptive (mid-treatment PET-based) chemoradiotherapy for stage III NSCLC—Results and comparison to NRG-RTOG 0617 (non-personalized RT dose escalation).
Authors
Feng-Ming Spring Kong
Clinical Oncology Department, The University of Hongkong-Shenzhen Hospital, Shenzhen, China
Feng-Ming Spring Kong , Chen Hu , Randall Ten Haken , Ying Xiao , Martha Matuszak , Vera Hirsh , Daniel A. Pryma , Barry A. Siegel , Daphna Y. Gelblum , James Hayman , Clifford Grant Robinson , Billy W. Loo , Gregory M.M. Videtic , Sergio Faria , Catherine Ferguson , Neal E. Dunlap , Vijayananda Kundapur , Rebecca Paulus , Jeffrey D. Bradley , Mitchell Machtay
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01507428
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8548)
DOI
10.1200/JCO.2021.39.15_suppl.8548
Abstract #
8548
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Associations between patient-reported nutritional status, survival, and toxicity among patients with limited stage small-cell lung cancer (LS SCLC) in a randomized trial of high-dose, twice-daily (BID) thoracic radiotherapy (TRT).
First Author: Evgenia Taranova
Poster
2013 ASCO Annual Meeting
Dose-escalation study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for stage III non-small cell lung cancer.
First Author: Naruo Yoshimura
Poster
2011 ASCO Annual Meeting
Endostar in combination with radiotherapy and paclitaxel/carboplatin in patients with unresectable non-small cell lung cancer of stage III: Preliminary results of a phase II study.
First Author: S. Ma
Poster
2011 ASCO Annual Meeting
Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC).
First Author: T. Stinchcombe